Combination of ofloxacin and amikacin in the treatment of sternotomy wound infection.
Mycobacterium fortuitum infection of soft tissue and wound (postoperative or otherwise) has been well reported in medical literature. In 1987, ten patients in our hospital with various cardiac diagnoses requiring open-heart surgery developed M fortuitum infection at the sternotomy site. As successful chemotherapy, in addition to surgical debridement, relies on in vitro susceptibility testing, ofloxacin and amikacin were thus assessed and found to have very satisfactory MIC. For the former: 1.25 mg/L for eight isolates, 2.5 mg/L for one isolate, and greater than 20 mg/L for one isolate were found. For the latter: 1 mg/L for six isolates, 2 mg/L for two isolates, and 4 mg/L and 8 mg/L for the remaining two isolates were found, respectively. These patients were given ofloxacin (300 mg once daily to 1,200 mg daily in divided doses) for three to six months and 500 mg amikacin daily (in two divided doses intravenously or intramuscularly) for three to eight weeks. The clinical outcome was favorable except for one patient who died of bacteremia due to M fortuitum coupled with many medical complications. Encouraged by these preliminary results, a future prospective study with ofloxacin as single agent for soft tissue, particularly postoperative sepsis due to M fortuitum, will be planned.
Yew
W W
WW
Tuberculosis and Chest Unit, Grantham Hospital, Wong Chuk Hang, Aberdeen, Hong Kong.
Kwan
S Y
SY
Ma
W K
WK
Aung-khin
M
M
Mok
C K
CK
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures / Q000009:adverse effects*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009164:Mycobacterium Infections / Q000188:drug therapy*; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy*; D009170:Nontuberculous Mycobacteria; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D013249:Sternum / Q000601:surgery*; D013530:Surgical Wound Infection / Q000188:drug therapy*
D004338:Drug Combinations; D000583:Amikacin; D015242:Ofloxacin